[
    [
        {
            "time": "",
            "original_text": "智飞生物：将持续做好产品进口、推广、销售等工作",
            "features": {
                "keywords": [
                    "智飞生物",
                    "产品",
                    "进口",
                    "推广",
                    "销售"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：将持续做好产品进口、推广、销售等工作",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：根据双方协议约定，默沙东向智飞生物独家供应协议疫苗产品，截至2020年末，公司累计签发HPV疫苗超过2500万剂",
            "features": {
                "keywords": [
                    "智飞生物",
                    "默沙东",
                    "HPV疫苗",
                    "独家供应",
                    "签发"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：根据双方协议约定，默沙东向智飞生物独家供应协议疫苗产品，截至2020年末，公司累计签发HPV疫苗超过2500万剂",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司重组结核杆菌融合蛋白（EC）于去年获批，截至目前已在广西、湖南、四川、浙江、山东等26个省级单位中标，该产品的推广工作也在积极推进中",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组结核杆菌融合蛋白",
                    "EC",
                    "中标",
                    "推广"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：公司重组结核杆菌融合蛋白（EC）于去年获批，截至目前已在广西、湖南、四川、浙江、山东等26个省级单位中标，该产品的推广工作也在积极推进中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司目前共有5种自主产品上市在售，1种产品紧急使用，包括ACYW135流脑多糖疫苗、AC结合疫苗、Hib疫苗、重组结核杆菌融合蛋白（EC）、注射用母牛分枝杆菌、重组新冠疫苗",
            "features": {
                "keywords": [
                    "智飞生物",
                    "自主产品",
                    "上市",
                    "重组新冠疫苗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：公司目前共有5种自主产品上市在售，1种产品紧急使用，包括ACYW135流脑多糖疫苗、AC结合疫苗、Hib疫苗、重组结核杆菌融合蛋白（EC）、注射用母牛分枝杆菌、重组新冠疫苗",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司目前生产经营正常",
            "features": {
                "keywords": [
                    "智飞生物",
                    "生产经营",
                    "正常"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物：公司目前生产经营正常",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：中国科学院微生物研究所与公司合作有中东呼吸综合症疫苗项目、重组新型冠状病毒疫苗（CHO细胞）项目",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中科院",
                    "微生物研究所",
                    "疫苗项目",
                    "中东呼吸综合症",
                    "重组新冠疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：中国科学院微生物研究所与公司合作有中东呼吸综合症疫苗项目、重组新型冠状病毒疫苗（CHO细胞）项目",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：根据公司与默沙东公司签署的相关协议，代理产品为四价HPV疫苗、九价HPV疫苗、五价轮状疫苗、23价肺炎疫苗、灭活甲肝疫苗，协议期限自2021年1月1日起至2023年6月30日止，目前公司该协议代理业务经营情况正常",
            "features": {
                "keywords": [
                    "智飞生物",
                    "默沙东",
                    "HPV疫苗",
                    "代理",
                    "协议"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：根据公司与默沙东公司签署的相关协议，代理产品为四价HPV疫苗、九价HPV疫苗、五价轮状疫苗、23价肺炎疫苗、灭活甲肝疫苗，协议期限自2021年1月1日起至2023年6月30日止，目前公司该协议代理业务经营情况正常",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司和中科院微生物研究所合作研发的重组新型冠状病毒疫苗（CHO细胞）达到WHO要求的新冠疫苗有效性标准，初步分析结果也显示出该产品对变异毒株不错的保护效力",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中科院",
                    "重组新冠疫苗",
                    "WHO",
                    "有效性",
                    "变异毒株",
                    "保护效力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：公司和中科院微生物研究所合作研发的重组新型冠状病毒疫苗（CHO细胞）达到WHO要求的新冠疫苗有效性标准，初步分析结果也显示出该产品对变异毒株不错的保护效力",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]